Erenumab is a monoclonal antibody to the receptor for calcitonin gene related peptide which plays a role in inducing migraine headaches. Erenumab is used for prevention of migraine in patients with episodic or chronic migraine headaches. Erenumab therapy has not been associated with serum enzyme elevations during therapy nor has it been implicated in cases of clinically apparent drug induced liver injury with jaundice.